Amoxicillin/clarithromycin pulsatile - AdvancisAlternative Names: Amoxicillin/clarithromycin PULSYS™; Pulsatile amoxicillin/clarithromycin; PULSYS™ amoxicillin/clarithromycin
Latest Information Update: 15 May 2007
At a glance
- Originator Advancis Pharmaceutical
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 15 May 2007 Discontinued - Phase-I/II for Bacterial infections in USA (PO)
- 01 Apr 2004 Phase-I/II clinical trials in Bacterial infections in USA (PO)